Wed, Aug 27, 2014, 12:11 PM EDT - U.S. Markets close in 3 hrs 49 mins

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

beavertail_splash 277 posts  |  Last Activity: 12 hours ago Member since: Apr 13, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Incyte just goes on plugging straight up.

    by golflogo Aug 13, 2014 11:11 AM
    beavertail_splash beavertail_splash Aug 13, 2014 2:40 PM Flag

    I thought you were at some beach in Maine frolicking?
    We are not jealous of INCY's comfort drug success but rather dumbfounded it defies any pure logic.

  • Reply to

    Zack says Sell

    by la.taupe Aug 13, 2014 9:36 AM
    beavertail_splash beavertail_splash Aug 13, 2014 2:32 PM Flag

    based their analysis on earnings, we need more such recommendations from them. up 5% is good

  • Reply to

    Incyte just goes on plugging straight up.

    by golflogo Aug 13, 2014 11:11 AM
    beavertail_splash beavertail_splash Aug 13, 2014 1:22 PM Flag

    INCY's drug dude is below average, in fact a complete failure when it comes to clinical remissions. He probably bribed his way through med school.

  • Reply to

    Incyte just goes on plugging straight up.

    by golflogo Aug 13, 2014 11:11 AM
    beavertail_splash beavertail_splash Aug 13, 2014 1:18 PM Flag

    Van you forgot to mention how your mediocre underachiever who transforms himself into a successful, supermodel dating biotech leader has also become an FDA influence peddling bully on his pharma turf using the $B's he's made selling snake comfort oil to unsuspecting cancer patients meanwhile hurting the competitors ability to market a potentially life saving drug.
    Facts speak for themselves. And the fact you are on this board promoting INCY speaks loudly from which lobby you're funding originates.

  • Every trial protocol is reviewed by FDA bfr. trials are ever approved. LFT reversibility follow up when the company was hit with this request twds the end of the P, ET proof in concept protocol reflects bad on the FDA's lack of consistency. None of GERON's previous trials(2 years of breast cancer trials) were ever halted for LFT concerns and yet this one, after showing CR's & PR's in the MAYO trial, a first in MF oncology treatment IMET was slapped with a full clinical hold.
    To me this all points to the work of the INCY lobbyists effectively at work on the FDA. Why hasn't Jakafi ever been halted for all it's serious toxicity issues? And yet the INCY "comfort drug" moves on gaining more indications based on weak comfort criteria.

  • Reply to

    Lawyers Out There?

    by blackmarango Aug 7, 2014 2:38 PM
    beavertail_splash beavertail_splash Aug 12, 2014 11:38 PM Flag

    Maybe total conjecture Irish but it would be priceless if indeed this was really the behind the scene story. Scarlet did repeat "high unmet medical need" at least several times in the CC. BTD is still possible. Now that Tefferi is in charge of the clinical trials & the FDA's appeased by this move possibly suggests BTD status might be @ BAT.

  • Reply to

    yellowsuban

    by tazamatic2002 Aug 12, 2014 1:19 PM
    beavertail_splash beavertail_splash Aug 12, 2014 9:05 PM Flag

    Isn't this a possible blessing in disguise because data not under the ASH submission embargo can be presented anytime such data becomes available? Such news would support IMET for a broader MDS indication base.

  • Reply to

    Those Who Misled

    by mruyog Aug 12, 2014 11:47 AM
    beavertail_splash beavertail_splash Aug 12, 2014 11:59 AM Flag

    so what was your take on the CC Chouffe?

  • Reply to

    What about Tefferi?

    by van_picasso Aug 12, 2014 9:22 AM
    beavertail_splash beavertail_splash Aug 12, 2014 10:43 AM Flag

    Chippy mentioned them in the CC and stated Tefferi hadn't the tme to review that data to submit it in the ASH data abstracts but would at some other opportunity.

  • Reply to

    expect nothing until Q1 2015

    by georgesmarsh Aug 11, 2014 5:03 PM
    beavertail_splash beavertail_splash Aug 12, 2014 9:55 AM Flag

    which means he's free to present abstracts for other indications not under the ASH submission embargo any time now.

  • Reply to

    What about Tefferi?

    by van_picasso Aug 12, 2014 9:22 AM
    beavertail_splash beavertail_splash Aug 12, 2014 9:35 AM Flag

    Hopefully this year he slips more info pre ASH. The blast phase MDS data is not under ASH data submission embargo.

  • Reply to

    End2War. - What did you hear? ?

    by kipk20122 Aug 11, 2014 5:17 PM
    beavertail_splash beavertail_splash Aug 12, 2014 9:13 AM Flag

    ...good post E2 even if you didn't listen to the CC yet. I agree something smells fishy in the state of Denmark for the FDA to have forced GERON around all these roadblocks.
    In the end of the day IMET in terms of efficacy has met the golden standard of remissions which even INCY and the FDA cannot deny.
    Hopefully Tefferi presents some blast, MDS data update on other indications in data not under ASH data submission embargo. This would further help validate wider indications. With the ET & PV hold in place many more of these previously treated patients could develop advanced MF where only IMET can promise remissions.
    Only disappointment was no mention of Chippy going fur BAT. Or maybe he's keeping that one guarded.

  • Reply to

    How the CC satisfied investors

    by spwangsu Aug 11, 2014 9:17 PM
    beavertail_splash beavertail_splash Aug 12, 2014 12:24 AM Flag

    Change management? Why? Chippy didn't accept a low ball offer.
    This has more to do with the INCY lobby than anything Chippy did or did not do. The ET & MM data from GERON's proof in concept IND study was the basis of the FDA's hold. All required data had been previously submitted by the company as advised by the liver experts they consulted & the FDA which gave initial approval to run the trial and required data. (Hy's Law). The FDA's timing; waiting till nearly after the study was completed to implement this clinical hold, allowing a full year to elapse prior to informing the company of the LFT follow up data needed. This timed with the stellar MAYO MF results raises question if the FDA acted independently or was influenced. The company was surprised by the FDA's hold & request with GERN's IND as it followed the unwinding of these studies.
    According to the CC any updated MF trial data will have to wait till ASH which is under ASH abstract submission embargo. Dec update expected with a hold lift possible bfr.
    MF's MDS & Blast phase data was not submitted by Teferri for ASH as time constraint on submissions to FDA partial lift was addressed and these updates were not available as a result. He will present this at another forum, possibly sooner than ASH.

  • beavertail_splash beavertail_splash Aug 9, 2014 11:04 PM Flag

    He means latest (newest) brochure from MAYO. What's noteworthy is that they don't even mention INCY's Ruxolitnib as a treatment for MF under their hematological cancer heading. Remissions trump comfort at the MAYO.

  • beavertail_splash by beavertail_splash Aug 9, 2014 7:25 AM Flag

    "Facts do not change with time. My views on ruxolitinib and other JAK inhibitors are based on facts from clinical trials and personal experience in using these drugs and they are comprehensively outlined in my recent reports in NEJM, Blood and the Mayo Clinic Proceedings Nothing has changed since other than the expected relentless effort by the drug companies and their sponsor-friendly colleagues to undermine important patient safety concerns and the therapeutic limitations of ruxolitinib. I, for one, have no interest in being a pharmaceutical sales scout and would rather spend my time and energy to seek new and better drugs for my patients. I am old enough to have seen a similar scenario in the past with the use of anagrelide in ET and PV.”

  • beavertail_splash beavertail_splash Aug 8, 2014 9:55 AM Flag

    time will tell. Monday should clear up some of the confusion going fwd. We'll see who's side Chippy is playing ball for. He's up at BAT come Monday.

  • beavertail_splash beavertail_splash Aug 8, 2014 9:43 AM Flag

    It's been a mystery!

  • beavertail_splash beavertail_splash Aug 8, 2014 9:41 AM Flag

    drug specific genetic oncology is the big medical push today. IMET is one such drug that has met this criteria in that it is gene specific and can sustain complete remissions in MF and AML patients.

  • beavertail_splash beavertail_splash Aug 7, 2014 10:17 AM Flag

    Unfortunately already passed too many wood 'chippy' looking pellets without ever feeling filled.

  • beavertail_splash beavertail_splash Aug 7, 2014 9:58 AM Flag

    To me Irish this reads like a red herring smells. Clearly the FDA appears to be acting complicit with INCY in preventing GERN's advancement in other applications such as ET, PV & AML's. Instead INCY with a jack all ``comfort`` drug worth billions to them has deceptively cornered this market. Unfortunately the patients being treated with it are never cured nor experience remissions and most discontinue as a result of serious side effects.

TSRX
13.63-0.05(-0.37%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.